Vascular endothelial dysfunction (VED) is linked with the pathogenesis of obstructive sleep
apnea (OSA) comorbidities, such as cardiovascular disease. Astragaloside IV (As-IV) has …

Background As the major pathophysiological feature of obstructive sleep apnea (OSA),
chronic intermittent hypoxia (CIH) is vital for the occurrence of cardiovascular complications …

Obstructive sleep apnea syndrome (OSAS) is an important consequence of chronic
intermittent hypoxia (CIH). Astragaloside IV (AS‐IV) exerts multiple protective effects in …

Astragaloside IV (AS-IV) has been used to treat cardiovascular disease. However, whether
AS-IV exerts a protective effect against hypertensive heart disease has not been …

Purpose Intermittent hypoxia is a characteristic pathological change in obstructive sleep
apnoea (OSA) that can initiate oxidative stress reaction and pro-inflammatory cytokine …

The Notch signaling pathway participates in pulmonary artery smooth muscle cell (PASMC)
proliferation and apoptosis. Astragaloside IV (AS‑IV) is an effective antiproliferative treatment …

Background: Endothelial barrier dysfunction plays a key role in atherosclerosis progression.
The primary pathology of obstructive sleep apnea-hypopnea syndrome is chronic …

Vascular endothelial dysfunction is associated with increased mortality in patients with
diabetes. Astragaloside IV (As‐IV) is a bioactive saponin with therapeutic potential as an anti …

Endothelial dysfunction is one of the main pathological changes in Obstructive sleep
apnoea (OSA). The Rho kinase (ROCK) pathway is associated with endothelial dysfunction …

Background Myocardial ischemia-reperfusion (I/R) causes damage to coronary capillary
endothelial barrier and microvascular leakage (MVL), aggravating tissue injury and heart …